# PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals Inc is a company headquartered in Malvern, PA, United States.

## Company overview

- **Legal name:** PhaseBio Pharmaceuticals Inc
- **Former names in filing history:** Phase Biosciences Inc (2006-09-18 to 2008-04-23); DT BIOSCIENCES INC (2002-02-25 to 2004-05-11)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Malvern, PA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001169245

## About

PhaseBio Pharmaceuticals Inc is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001169245, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2022-03-24, it reported annual revenue of USD 10,831,000; net income of USD -131,071,000; total assets of USD 60,540,000 for the fiscal period ended 2021-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $10.8M (USD 10,831,000)
- **Net income:** -$131.1M (USD -131,071,000)
- **Total assets:** $60.5M (USD 60,540,000)
- **Cash and equivalents:** $41.8M (USD 41,800,000)
- **Operating cash flow:** -$47.4M (USD -47,416,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $320,000 (USD 320,000)
- **Net income:** -$98.6M (USD -98,565,000)
- **Total assets:** $50.4M (USD 50,357,000)
- **Cash and equivalents:** $28.1M (USD 28,122,000)
- **Operating cash flow:** -$60.0M (USD -59,957,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $2.4M (USD 2,361,000)
- **Net income:** -$39.2M (USD -39,247,000)
- **Total assets:** $82.5M (USD 82,494,000)
- **Cash and equivalents:** $74.0M (USD 74,025,000)
- **Operating cash flow:** -$39.6M (USD -39,594,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $668,000 (USD 668,000)
- **Net income:** -$23.8M (USD -23,846,000)
- **Total assets:** $63.0M (USD 63,026,000)
- **Cash and equivalents:** $61.0M (USD 61,031,000)
- **Operating cash flow:** -$17.1M (USD -17,053,000)

## Recent SEC filings

- Form 8-K — filed 2024-08-15 — period 2024-07-26 — 8-K
- Form 8-K — filed 2024-07-12 — period 2024-05-23 — 8-K
- Form 8-K — filed 2024-05-16 — period 2024-03-22 — 8-K
- Form 8-K — filed 2024-03-12 — period 2024-03-06 — 8-K
- Form 8-K — filed 2023-11-29 — period 2023-11-17 — 8-K
- Form 8-K — filed 2023-10-03 — period 2023-09-27 — 8-K
- Form 8-K — filed 2023-09-27 — period 2023-09-22 — 8-K
- Form 8-K — filed 2023-08-25 — period 2023-07-24 — 8-K
- Form 8-K — filed 2023-06-30 — period 2023-06-22 — 8-K
- Form 8-K — filed 2023-05-30 — period 2023-05-23 — 8-K
- Form 8-K — filed 2023-05-10 — period 2023-05-04 — 8-K
- Form 8-K — filed 2023-03-24 — period 2023-03-21 — 8-K

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/phasebio-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology